Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
(Date:10/19/2014)... The report "Unmanned Ground Vehicle Market by ... Type & by Geography - Forecasts & Analysis ... vehicle market into various sub segments with an ... report also identifies the factors driving this market, ... the adoption trends. , The unmanned ground vehicle ...
(Date:10/18/2014)... The “Human Insulin Market- by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/18/2014)... October 18, 2014 The report ... Trends and Forecasts to 2019", analyzes the global ... order to understand the industry details such as ... across various geographic regions. , Browse 81 Market ... Slides and in-depth TOC on “1,6-Hexanediol Market by ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 51,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5
... New DNA-Based Test Produces Decisive Result Within ... Enigma Diagnostics,the life sciences company developing ... it has successfully completed a project,commissioned by ... to,develop a rapid, point-of-care diagnostic system for ...
... Agreement in Principle with U.S. Attorney,s Office; ... Earnings Exceed Company Guidance;,Company Again ... Pa., Nov. 8 Cephalon, Inc. (Nasdaq:,CEPH) today reported third ... $457.2 million for the third quarter of 2006 and,within the ...
... ExonHit Therapeutics, a,drug and diagnostic discovery company, has ... test. The company expects to have,this test certified ... its GLP (Good,Laboratory Practices) compliant laboratories to the ... ExonHit test aims to identify patients suffering from,Alzheimer,s ...
Cached Biology Technology:Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 2Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 3Cephalon Announces Strong Third Quarter Financial Results 2Cephalon Announces Strong Third Quarter Financial Results 3Cephalon Announces Strong Third Quarter Financial Results 4Cephalon Announces Strong Third Quarter Financial Results 5Cephalon Announces Strong Third Quarter Financial Results 6Cephalon Announces Strong Third Quarter Financial Results 7Cephalon Announces Strong Third Quarter Financial Results 8Cephalon Announces Strong Third Quarter Financial Results 9Cephalon Announces Strong Third Quarter Financial Results 10Cephalon Announces Strong Third Quarter Financial Results 11Cephalon Announces Strong Third Quarter Financial Results 12Cephalon Announces Strong Third Quarter Financial Results 13Cephalon Announces Strong Third Quarter Financial Results 14Cephalon Announces Strong Third Quarter Financial Results 15Cephalon Announces Strong Third Quarter Financial Results 16Cephalon Announces Strong Third Quarter Financial Results 17Cephalon Announces Strong Third Quarter Financial Results 18ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/16/2014)... Conn. , October 16, 2014 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... its leading edge technologies including Wocket™, the Smart Wallet, ... (FiRe) Conferenece. FiRe is a leading global conference on ... Hosted by Mark Anderson , founder and ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Sanctuary have collected the first camera trap video footage ... individuals remaining, Cross River gorillas are the world,s rarest ... by field researchers. Collected from one of four ... protected area, the footage reveals eight Cross River gorillas ...
... CUNY Energy Institute, which has been developing innovative low-cost ... discharge rates and high energy densities, announced that it ... The Institute said large-scale commercialization of the battery would ... an environmentally friendlier and less costly alternative to nickel ...
... to develop more efficient biofuel cells, seen as the future ... biological materials, they have the potential to be used indefinitely ... possible to replace a battery or recharge them. , Most ... the Leeds research will focus on bacterial enzymes that can ...
Cached Biology News:Camera trap video offers rare glimpse of world's rarest gorilla 2CUNY Energy Institute battery system could reduce buildings' electric bills 2Creating energy from light and air - new research on biofuel cells 2
Cytofix Buffer 100 mls...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Perm/Wash Buffer 250 Tests...
PCR purification kit, 100 preps...
Biology Products: